AnaSpec Introduces Line of Insulin Receptor Antibodies

San Jose, CA, May 23, 2007 --(PR.com)-- The insulin receptor is a transmembrane receptor that belongs to the tyrosine kinase receptors class. It is a heterotetrameric glycoprotein composed of disulfide-linked subunits in a β-α-α-β configuration. This transmembrane receptor consists of 95kDa β-subunit, a single transmembrane domain, and 135kDa α-subunit, which is completely extracellular. Binding of insulin to the receptor results in stimulation of its intrinsic kinase activity. The insulin receptor mediates insulin action through the phosphorylation of substrate proteins. Insulin receptor becomes phosphorylated as a response to stimulation of cells by insulin, insulin-like growth factor (IGF-I) and interleukin 4. The major substrates of the insulin receptor kinase are the insulin receptor substrate (IRS) family of proteins, IRS-1, IRS-2, IRS-3, IRS-4. Recently, two more signaling proteins, IRS5/DOK4 and IRS6/DOK5, have been identified as potentially new members of the IRS family. The insulin receptor substrate-1 (IRS-1), a 170-185 kDa protein, is a major substrate of the insulin receptor. IRS-1 is phosphorylated on serine, threonine and tyrosine residues in a variety of tissues.

AnaSpec offers a line of insulin receptor antibodies that targets researchers working in protein phosphorylation, glucose metabolism, cancer, and diabetes studies. These antibodies are validated on ELISA, and Western Blot or IHC, and offered in research-grade size.

For more information visit www.anaspec.com

Company Info

AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and combinatorial chemistry. Established in 1993, AnaSpec's ISO9001:2000 certified headquarters and manufacturing facilities are located in San Jose, CA.

###